Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) and Zealand Pharma A/S (NASDAQ:ZEAL) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals Inc.	N/A	0.00	20.65M	-0.63	0.00
Zealand Pharma A/S	N/A	0.00	N/A	3.00	5.18

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Verrica Pharmaceuticals Inc. and Zealand Pharma A/S.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals Inc.	0.00%	0%	0%
Zealand Pharma A/S	0.00%	0%	0%

Analyst Ratings

The table shown features the ratings and recommendations for Verrica Pharmaceuticals Inc. and Zealand Pharma A/S.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Verrica Pharmaceuticals Inc.	0	0	1	3.00
Zealand Pharma A/S	0	0	0	0.00

The consensus price target of Verrica Pharmaceuticals Inc. is $20, with potential upside of 90.84%.

Institutional and Insider Ownership

Institutional investors owned 33% of Verrica Pharmaceuticals Inc. shares and 9.28% of Zealand Pharma A/S shares. Insiders owned 44.5% of Verrica Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Verrica Pharmaceuticals Inc.	14.99%	5.76%	8.39%	-26.22%	0%	55.34%
Zealand Pharma A/S	6.55%	7.93%	34.59%	9.24%	-2.23%	33.89%

For the past year Verrica Pharmaceuticals Inc. has stronger performance than Zealand Pharma A/S

Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is headquartered in West Chester, Pennsylvania.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.